Latest Articles

Publication Date
Glucagon-like peptide-1 receptor agonists may reduce endometrial cancer risk in endometrial hyperplasia - 2 Minute Medicine

Glucagon-like peptide-1 receptor agonists may reduce endometrial cancer risk in endometrial hyperplasia 2 Minute Medicine

Published: Feb. 17, 2026, 12:15 a.m.
Atypical gelation of Elagolix sodium in aqueous media: Mechanistic insights and Inhibition via coamorphization.

Elagolix sodium (ELS), a non-peptide oral gonadotropin-releasing hormone receptor (GnRH) antagonist approved for the treatment of endometriosis-associated pain, displays atypical gelation in aqueous environments along with challenging physical properties such …

Published: Feb. 12, 2026, midnight
The Hidden Link Between Endometriosis and Obesity: A State-of-the-Art Review.

Endometriosis remains an under-researched disease with a wide range of symptoms. Endometriosis reduces a woman's quality of life and professional productivity, yet its exact causes, risk factors, and treatment have …

Published: Feb. 3, 2026, midnight
Influence of Oxidative Stress-Mediated Inflammation on the Pathogenesis of Reproductive Disorders: Exploring the Benefits of Carnosine for Prevention and Treatment of Endometriosis.

Endometriosis is a chronic pathological condition characterized by the growth of endometrial-like tissue outside the uterine cavity and is frequently associated with severe pain, persistent inflammation, and fibrosis within the …

Published: Jan. 30, 2026, midnight
Copper-Targeted Therapy in Experimental Endometriosis: Effects of Ammonium Tetrathiomolybdate on Markers of the Interconnected Processes of Inflammation, Innervation, and Fibrogenesis.

Endometriosis (EDT) is a chronic, estrogen-dependent disease characterized by inflammation, fibrosis, pelvic pain, and infertility. Current therapies show limited long-term efficacy and adverse effects, underscoring the need for novel therapeutic …

Published: Jan. 22, 2026, midnight
Pharmacokinetic-Pharmacodynamic Modeling and Simulation of Merigolix, a Nonpeptide Gonadotropin-Releasing Hormone Antagonist.

Gonadotropin-releasing hormone (GnRH) antagonists inhibit estrogen synthesis and secretion, making them promising treatment options for estrogen-dependent diseases, such as endometriosis. This study developed a population pharmacokinetic/pharmacodynamic (PK/PD) model for merigolix, …

Published: Dec. 20, 2025, midnight
Effect of kisspeptin, neurokinin, and dynorphin neurons on regulation of reproduction.

Gonadotropin-releasing hormone pulsatility is under the influence of hypothalamic neuropeptides, especially neurons expressing kisspeptin, neurokinin B, and dynorphin. These hypothalamic cells are called KNDy neurons. By integrating hormonal and environmental …

Published: Nov. 1, 2025, midnight
Anti-Angiogenic RNAi-Based Treatment of Endometriosis in a Rat Model Using CXCR4-Targeted Peptide Nanoparticles.

Endometriosis is a common gynecological condition that affects fertility in many women of reproductive age worldwide. This multifaceted disease exhibits a pathogenesis characterized by hormonal and immune system dysregulations, alongside …

Published: Oct. 30, 2025, midnight
A Dual-Targeted Liposomal Nanosystem for Co-Delivery of Estrogen Receptor β Antagonist and Disulfiram for the Non-Hormonal Treatment of Endometriosis.

Endometriosis is an estrogen-dependent disease that severely affects the physical and mental health of women of childbearing age. Due to the significant side effects of traditional hormone therapies, non-hormonal treatment …

Published: Oct. 29, 2025, midnight
Predicted peptide scaffolds for drug screening in endometrial cancer organoids - Nature

Predicted peptide scaffolds for drug screening in endometrial cancer organoids Nature

Published: Oct. 27, 2025, 2:22 p.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!